Rhabdomyolysis with the combined use of danazol and rosuvastatin in left ventricular assist devices

J Heart Lung Transplant. 2020 May;39(5):498-500. doi: 10.1016/j.healun.2020.02.006. Epub 2020 Feb 13.

Authors

Shivank Madan¹, Mandeep R Mehra²

Affiliations

¹ Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. Electronic address: samadan@bwh.harvard.edu.
² Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts.

PMID: 32122697
DOI: 10.1016/j.healun.2020.02.006

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
COVID-19 / epidemiology*
Comorbidity
Danazol / therapeutic use*
Drug Therapy, Combination
Estrogen Antagonists / therapeutic use
Heart Failure / epidemiology
Heart Failure / therapy*
Heart-Assist Devices*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Male
Middle Aged
Rhabdomyolysis
Rosuvastatin Calcium / therapeutic use*
Treatment Outcome

Substances

Estrogen Antagonists
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Rosuvastatin Calcium
Danazol